Ocugen (OCGN) to Release Earnings on Tuesday

Ocugen (NASDAQ:OCGN - Get Free Report) is scheduled to issue its quarterly earnings data before the market opens on Tuesday, May 14th. Analysts expect the company to announce earnings of ($0.06) per share for the quarter. Investors interested in participating in the company's conference call can do so using this link.

Ocugen (NASDAQ:OCGN - Get Free Report) last released its quarterly earnings results on Tuesday, April 16th. The company reported ($0.04) EPS for the quarter. The business had revenue of $6.04 million for the quarter. On average, analysts expect Ocugen to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Ocugen Stock Down 3.7 %

Shares of Ocugen stock traded down $0.06 on Tuesday, reaching $1.57. The stock had a trading volume of 6,471,430 shares, compared to its average volume of 7,945,316. The stock has a market capitalization of $404.01 million, a P/E ratio of -5.81 and a beta of 3.49. Ocugen has a 1 year low of $0.35 and a 1 year high of $2.11. The company has a quick ratio of 2.51, a current ratio of 2.51 and a debt-to-equity ratio of 0.07. The company has a 50 day moving average price of $1.35 and a 200 day moving average price of $0.81.

Wall Street Analysts Forecast Growth

OCGN has been the subject of several recent analyst reports. Chardan Capital raised their price target on Ocugen from $4.00 to $5.00 and gave the stock a "buy" rating in a report on Monday, April 22nd. HC Wainwright reissued a "buy" rating and set a $7.00 target price on shares of Ocugen in a research report on Wednesday, April 3rd.

About Ocugen

Ocugen, Inc, a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease.